Direkt zum Inhalt
Merck
  • The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study.

The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study.

The Journal of clinical endocrinology and metabolism (2004-05-06)
Boryana Todorova, Agata Kubaszek, Jussi Pihlajamäki, Jaana Lindström, Johan Eriksson, Timo T Valle, Helena Hämäläinen, Pirjo Ilanne-Parikka, Sirkka Keinänen-Kiukaanniemi, Jaakko Tuomilehto, Matti Uusitupa, Markku Laakso
ZUSAMMENFASSUNG

In population-based studies, dyslipidemia related to insulin resistance (high triglyceride level and low high-density lipoprotein cholesterol level) is a risk factor for type 2 diabetes. Therefore, variants in genes regulating lipid and lipoprotein metabolism are potential candidate genes for diabetes. We investigated whether the G-250A polymorphism of the hepatic lipase gene (LIPC) predicts the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in the Finnish Diabetes Prevention Study. This study randomized subjects to either the intervention group (lifestyle modification aimed at weight loss, such as changes in diet and increased physical exercise) or the control group. Genotyping at position -250 of the LIPC gene was performed with PCR amplification, DraI enzyme digestion, and gel electrophoresis in 490 subjects with IGT whose DNA was available. In the entire study population, the conversion rate to type 2 diabetes was 17.8% among subjects with the G-250G genotype and 10.7% among subjects with the -250A allele (P = 0.032). In univariate analysis, the odds ratio for the G-250G genotype to predict the conversion from IGT to type 2 diabetes was 1.80 (95% confidence interval, 1.05-3.10; P = 0.034). In multivariate logistic regression analysis, the G-250G genotype predicted the conversion to diabetes independently of the study group (control or intervention), gender, weight, waist circumference at baseline, and change in weight and waist circumference. In the intervention group, 13.0% of subjects with the G-250G genotype and 1.0% of the subjects with the -250A allele converted to diabetes (P = 0.001). We conclude that the G-250G genotype of the LIPC gene is a risk factor for type 2 diabetes. Therefore, genes regulating lipid and lipoprotein metabolism may be potential candidate genes for type 2 diabetes.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Lipase aus Candida rugosa, Type VII, ≥700 unit/mg solid
Sigma-Aldrich
Lipase aus Schweinepankreas, Type II, ≥125 units/mg protein (using olive oil (30 min incubation)), 30-90 units/mg protein (using triacetin)
Sigma-Aldrich
Lipase-Acrylharz aus Candida antarctica, ≥5,000 U/g, recombinant, expressed in Aspergillus niger
Sigma-Aldrich
Lipase B Candida antarctica, rekombinant aus Aspergillus oryzae, powder, beige, ~9 U/mg
Sigma-Aldrich
Lipase aus Schweinepankreas, Type VI-S, ≥20,000 units/mg protein, lyophilized powder
Sigma-Aldrich
Lipase aus Aspergillus niger, powder (fine), ~200 U/g
Sigma-Aldrich
Lipase aus Candida rugosa, lyophilized powder, ≥40,000 units/mg protein
Sigma-Aldrich
Lipase aus Candida sp., recombinant, expressed in Aspergillus niger
Sigma-Aldrich
Lipase, immobilisiert aus Candida antarctica, beads, slightly brown, >2 U/mg
Sigma-Aldrich
Lipase aus Rhizomucor miehei, ≥20,000 U/g
Sigma-Aldrich
Lipase aus Pseudomonas cepacia, powder, light beige, ≥30 U/mg
Sigma-Aldrich
Lipase aus Weizenkeimen, Type I, lyophilized powder, 5-15 units/mg solid
Sigma-Aldrich
Lipase aus Rhizopus oryzae, powder (fine), ~10 U/mg
Sigma-Aldrich
Lipase aus Candida rugosa, powder, yellow-brown, ≥2 U/mg
Sigma-Aldrich
Lipase aus Pseudomonas sp., Type XIII, lyophilized powder, ≥15 units/mg solid
Sigma-Aldrich
Lipase aus Aspergillus oryzae, lyophilized, powder, white, ~50 U/mg
Sigma-Aldrich
Lipase aus Candida rugosa, lyophilized, powder (fine), 15-25 U/mg
Sigma-Aldrich
Lipase aus Mucor miehei, lyophilized powder, ≥4,000 units/mg solid (using olive oil)
Sigma-Aldrich
Lipase aus Rhizopus niveus, powder (fine), ≥1.5 U/mg
Sigma-Aldrich
Lipase A Candida antarctica, rekombinant aus Aspergillus oryzae, powder, beige, ~2 U/mg
Sigma-Aldrich
Lipase aus Mucor miehei, powder, slightly brown, ~1 U/mg
Sigma-Aldrich
Lipase aus Mucor javanicus, lyophilized powder, ≥300 units/mg solid (using olive oil)